|Mid quarter call tightens ranges at the upper end of estimates. Look for $2.08 as the new 2002 estimate. Sales for the year will easily eclipse $3 billion.|
CRM division is knocking the cover off the ball. IF momentum continues apace: The CRM division will shortly be worth around $30 per share on its own. (B/C Sales next year in this CRM division may top $1.8 billion. At 5 times sales on a product with mid 70% gross margins and an operating margin North of 20% and very large cash conversion rates on net income should be worth a multiple on sales)
I agree with some wags that the Cook acquisition is really just a $50 million option (breakup fee) on the stent market. Have to wait until mid September to find out what the judge has to say on enjoining the Cook/GDT stent data. I have no earthly idea as to handicaping how the judge will rule.
Anyone have a different take or am I the only one posting on this board anymore?